Genotype of Mild 6-pyruvoyl-tetrahydropterin Synthase Deficiency: Three Case Reports and a Literature Review
Objectives: To analyse the characteristics of mutation in PTS gene in Chinese patients with mild 6-pyruvoyl-tetrahydropterin synthase deficiency (M-PTSD). Methodology: Clinical and genetic data of three newborns with M-PTSD were collected from the Newborn Screening Center of Zhejiang Province, China. The characteristics of gene mutation in the selected patients were analysed together with local and international literature related to PTS gene and M-PTSD. Results: Nine M-PTSD patients have been reported in China, including three with the IVS1-291A>G/D96N genotype, two with the L93M/ N52S genotype, and one each with the IVS1-291A>G/N52S, IVS1-291A>G/L127F, V56M/R25G, and V56M/T106M genotypes. Four M-PTSD patients have been reported abroad: one each with the genotypes IVS1-322A>T/IVS1-322A>T, L26F/V124L, N47D/D116G, and R16C/C370_383 (K120→stop). Conclusion: Results showed ethnic differences in the M-PTSD related mutations. In the Chinese population, IVS1-291A>G, L93M, and V56M are mild-type mutations, and IVS1-291A>G is the most common benign mutation (27.8%). M-PTSD is not rare among individuals from mainland China, and newborns screened with PTSD should undergo mutation detection as soon as possible in order for physicians to select the appropriate therapeutic regimen and avoid over-treatment.
Keyword : 6-pyruvoyl-tetrahydropterin synthase deficiency; Medication treatment; Mutation; Tetrahydropterin deficiency
6-pyruvoyl-tetrahydrobiopterin synthase deficiency (PTSD) is the most common type of tetrahydrobiopterin deficiency around the world.1-3 It represents a heterogeneous group of progressive neurological disorders caused by autosomal recessively inherited mutations affecting 6-pyruvoyl-tetrahydropterin synthase (PTS), the second enzyme in the biosynthetic pathway for tetrahydrobiopterin (BH4).1,2 As assessed by cerebrospinal fluid (CSF) measurement of catecholamines and serotonin metabolites or clinical outcomes, it is divided into at least two different phenotypes, the more common severe central form and the rare mild peripheral form.1-2 Recently more and more PTSD cases were found in China due to more newborn screening and differential diagnosis being performed for hyperphenylalaninaemia (HPA).4 Many of the PTSD diagnosed late are retarded2 and it is difficult to distinguish mild (M-PTSD) from severe types, so that these newborns were often treated by combination therapy with BH4, dopamine and serotonin immediately. Meanwhile, the rapid development of sequencing technology and the study for relationship between genotype and phenotype of PTSD make it possible to diagnose M-PTSD by genotype. But reports about it are still scarce.
Between September 1999 and June 2014, there are 5,912,779 newborns screened for HPA at the Newborn Screening Center of Zhejiang Province, China. Of these, 35 PTSD were diagnosed. The incidence of PTSD was 1 in 168,937, including three cases of M-PTSD. We report the details of these three cases in the present study.
Methods and Results
Genetic examination: Genetic examination was conducted after informed consent was obtained from the parents. Peripheral blood specimens of the newborns and their parents were collected. Total DNA was extracted from the blood spots by using QIAamp DNA Investigator Kit(Qiagen GmbH, Hilden, Germany).
Mutation genotyping was performed using polymerase chain reaction (PCR). The Typer 4.0 genotyping software (Sequenom, San Diego, CA, USA) was used to design PCR primers and single-base extension assays of mutation sites. All primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). PCR was performed using reagents and an iPLEX Gold reagent kit from Sequenom (San Diego, CA, USA).
Mass spectrometry was conducted using the Nanodispenser RS1000 and MassARRAY Analyzer 4 systems with Typer 4.0 software (Sequenom).
The patient was a male born at 40 weeks of gestation with a birth weight (BW) of 3.7 kg. Newborn screening on Day 3 after birth showed increased blood phenylalanine (Phe) levels and Phe-to-tyrosine ratio (Phe/Tyr), i.e., 257 mmol/L (range, 23-100 mmol/L) and 2.52 (range, 0.1-1.5) respectively. The BH4 loading test was positive, urinary pterin analysis showed low biopterin / ( biopterin+ neopterin) [B%], and dihydropteridine reductase (DHPR) activity showed normal, which suggested the diagnosis of PTSD (Table 1). Combination therapy was immediately implemented. The patient is now 5 years and 6 months, with normal clinical outcomes (Table 1). PTSD was finally diagnosed by PTS gene mutation detection at age 4 years (Figure 1).
The patient was a female born at 39 weeks of gestation with a BW of 3.5 kg. Newborn screening on Day 3 showed elevated blood Phe levels (156 mmol/L) and Phe/Tyr ratio (1.8). Urinary pterin analysis and a DHPR activity assay suggested the diagnosis of PTSD. The patient was suggested to have the above-mentioned combination therapy, but rejected by her parents. Diagnosis was made using PTS gene mutation detection after one month (Figure 1). At present, the patient is 21 months old and has normal clinical outcomes (Table 1).
The patient was a male born at 37 weeks of gestation with a BW of 3.1 kg. Screening showed blood Phe levels of 248 mmol/L. Results of urinary pterin analysis and a DHPR activity assay suggested PTSD, which was finally diagnosed by gene detection (Figure 1). His parents did not allow any medication but agreed for follow up. Now the patient is 18 months old with normal clinical outcomes (Table 1).
The parents of all three newborns were of Han nationality (Chinese), all in good health and from non-consanguineous family. The patients' births were all natural, with a mean Apgar score of 10.
A keyword search of "PTSD" in the Chinese databases VIP (http://www.cqvip.com) and CNKI (http://www.cnki.net) (before June 2014) yielded 4 studies on M-PTSD patients carrying the PTS gene. Of these, cases 4 and 5 were siblings, a sister and brother, respectively (Table 1). A keyword search of "PTSD" and "PTS" in the international database PubMed (http://www.ncbi.nlm.nih.gov/pubmed) (before June 2014) yielded 6 studies on M-PTSD genes (Table 1).
M-PTSD accounted for 8.6% (3/35) of all PTSD cases in our hospital, and 12.5%,1 20%2 respectively from previous reports. All patients, whether treated nor untreated, were normal clinically during follow-up (Table 1). Nine M-PTSD patients have been reported in China, including 6 from previous reports and 3 from this report (Table 1). While four M-PTSD patients have been reported abroad (Table 1). In China, IVS1-291A>G accounts for 27.8% (5/18) of M-PTSD mutation sites. Splicing and missense mutations are the majority mutation types for M-PTSD(Table 1).
The incidence of PTSD is significantly higher in the Chinese (especially the southern Chinese population) than in Caucasians.1 In recent years, an increasing number of PTSD patients have been identified because of widespread screening for HPA. In China, PTSD is commonly diagnosed by the BH4 loading test, urinary pterin analysis, and DHPR activity assay. Gene detection has not been used extensively. Severe PTSD affects brain neurotransmitter (NTM) levels and generally has a poor prognosis. Once diagnosed, early PTSD is often treated by combination therapy with BH4, dopamine, and serotonin.4
Clinically, PTSD can be divided into the severe type and the mild type. M-PTSD does not significantly changes brain NTM levels but only increases blood Phe level; it causes no other neurological symptoms and therefore generally requires no treatment or single BH4 to maintain normal Phe level.2 In the present study, the blood Phe levels detected during newborn screening for M-PTSD varied from 247 to 1100 mmol/L. The data suggests that mild and severe types of PTSD cannot be distinguished solely on the basis of blood Phe levels. Dudesek et al2 found that L26F, V124L showed no measurable PTS activity in COS-1 cells but the heterozygote with L26F and V124L showed M-PTSD. It was suggested that the PTS enzyme activity assay was also ineffective in distinguishing between the mild and severe types. Although NTM levels in the CSF are indicative of M-PTSD,2 CSF examination is invasive and therefore may not find widespread clinical application, and it was rarely accepted by patients' parents in China.
In 1992, Thöny et al first cloned the PTS gene,5 which is positioned at 11q22.3-23.3 and comprises 6 exons. To date, more than 80 mutations in PTS gene have been reported in the HGMD database, and there are some reports about the correlation between PTSD phenotype and genotype.1-3 We summarised information on 18 alleles of 9 M-PTSD patients from mainland China and found IVS1-291A>G to be the most common mutation (27.8%). Further, in our cases, when the patient carried the IVS1-291A>G or L93M genotypes, even if the other allele was associated with severe-type PTSD, the symptoms manifested as M-PTSD. Similarly, Liu et al6 reported a heterozygous V56M mutation that clinically manifested as M-PTSD. Our data showed splicing and missense mutations are the majority mutation types for M-PTSD and the M-PTSD genotype was very different between Chinese and other populations.
Data also showed that M-PTSD accounted for 8.6%-20% of all PTSD cases. IVS1-291A>G was previously found as a hotspot mutation of the PTS gene in Chinese,1 suggesting that mild-type PTSD gene is not rare in Chinese.
Thus, M-PTSD related mutations show ethnic differences and are not rare in the Chinese population. IVS1-291A>G, L95M, and V56M in PTS gene are mild-type PTSD related mutations in Chinese, and IVS1-291A>G is the most common mutation. We recommend that early genetic testing be performed in newborns identified with PTSD by screening in order to select an appropriate therapeutic regimen and thereby avoid wasting energy and financial resources caused by over-treatment.
The written informed consent was obtained from the parents of the children who served as subjects of the investigation. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This paper was supported by Health Department of Zhejiang Province,China(2014KYA124) and Education Department of Zhejiang Province, China(Y201328502).
The authors declare that they have no competing interest.
1. Gu MQ, Ye J, Qiu WJ, Han LS, Zhang YF, Gu XF. Mutational analysis of patients with 6-pyruvoyltetrahydropterin synthesis deficiency. Chin J Med Genet 2009;26:183-6.
2. Dudesek A, Roschinger W, Muntau AC, et al. Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. Eur J Pediatr 2001;160:267-76.
3. Thony B, Leimbacher W, Blau N, Harvie A, Heizmann CW. Hyperphenylalaninemia due to defects in tetrahydrobiopterin metabolism: molecular characterization of mutations in 6-pyruvoyl-tetrahydropterin synthase. Am J Hum Genet 1994;54:782-92.
4. Ye J, Gu XF, Zhang YF, Huang XD, Gao XL, Chen RG. Diagnosis, treatment, and gene detection in 769 cases with hyperphenylalaninemia. Zhong Hua Er Ke Za Zhi 2002;40:210-3.
5. Thöny B, Leimbacher W, Burgisser D, Heizmann CW. Human 6-pyruvoyltetrahydropterin synthase: cDNA cloning and heterologous expression of the recombinant enzyme. Biochem Biophys Res Commun 1992;189:1437-43.
6. Liu TT, Hsiao KJ, Lu SF, et al. Mutation analysis of the 6-pyruvoyl-tetrahydropterin synthase gene in Chinese hyperphenylalaninemia caused by tetrahydrobiopterin synthesis deficiency. Hum Mutat 1998;11:76-83.
7. Qu YJ, Song F, Jin YW. Mutation analysis and one novel mutation detection of 6- pyruvoyl-tetrahydropterin synthase gene in children with tetrahydropterin deficiency. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2008;30:170-4.
8. Yang YL, QI Y, Shi CY, et al. Clinical and biochemical study for the diagnosis, treatment and prenatal diagnosis of tetrahydrobiopterin deficiency due to 6-pyruvoyltetrahydropterin synthesis deficiency. Chin J Pediatr Med 2004;7:349-52.
9. Meili D, Kralovicova J, Zagalak J, et al. Disease-causing mutations improving the branch site and polypyrimidine tract: pseudoexon activation of LINE-2 and antisense Alu lacking the poly(T)-tail. Hum Mutat 2009;30:823-31.
10. Scherer-Oppliger T, Matasovic A, Laufs S, et al. Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. Human mutation 1999;13:286-9.